- Home
- GNRC vs VRNA Comparison
GNRC vs VRNA Comparison
Compare GNRC & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNRC
- VRNA
- Stock Information
- Founded
- GNRC 1959
- VRNA 2005
- Country
- GNRC United States
- VRNA United Kingdom
- Employees
- GNRC N/A
- VRNA N/A
- Industry
- GNRC Metal Fabrications
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- GNRC Consumer Discretionary
- VRNA Health Care
- Exchange
- GNRC Nasdaq
- VRNA Nasdaq
- Market Cap
- GNRC 7.5B
- VRNA 8.3B
- IPO Year
- GNRC 2010
- VRNA 2017
- Fundamental
- Price
- GNRC $151.35
- VRNA $91.89
- Analyst Decision
- GNRC Buy
- VRNA Strong Buy
- Analyst Count
- GNRC 18
- VRNA 9
- Target Price
- GNRC $170.72
- VRNA $112.56
- AVG Volume (30 Days)
- GNRC 1.0M
- VRNA 1.1M
- Earning Date
- GNRC 07-30-2025
- VRNA 08-07-2025
- Dividend Yield
- GNRC N/A
- VRNA N/A
- EPS Growth
- GNRC 58.27
- VRNA N/A
- EPS
- GNRC 5.74
- VRNA N/A
- Revenue
- GNRC $4,348,682,000.00
- VRNA $118,535,000.00
- Revenue This Year
- GNRC $5.47
- VRNA $891.79
- Revenue Next Year
- GNRC $6.75
- VRNA $78.94
- P/E Ratio
- GNRC $26.55
- VRNA N/A
- Revenue Growth
- GNRC 8.07
- VRNA N/A
- 52 Week Low
- GNRC $99.50
- VRNA $15.15
- 52 Week High
- GNRC $195.94
- VRNA $99.01
- Technical
- Relative Strength Index (RSI)
- GNRC 79.62
- VRNA 55.59
- Support Level
- GNRC $140.75
- VRNA $92.88
- Resistance Level
- GNRC $143.70
- VRNA $97.44
- Average True Range (ATR)
- GNRC 3.58
- VRNA 3.34
- MACD
- GNRC 2.01
- VRNA -1.05
- Stochastic Oscillator
- GNRC 97.39
- VRNA 9.89
About GNRC Generac Holdlings Inc.
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.